Prostate disorder

This study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…

This study tests a new drug, AMO959, combined with a targeted radiation therapy (Pluvicto) and a hormone therapy in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has stopped responding to prior hormone treatment. The trial has two phases: first t…

This study tests whether adding the chemotherapy drug docetaxel to the usual hormone therapy and apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 men will be randomly assigned to receive either the three-drug combinati…

This phase 3 trial for men with advanced, hormone-resistant prostate cancer tests whether giving the drug lutetium-177 PSMA less often (only when the disease shows signs of activity) can improve quality of life without shortening survival. About 1,500 participants will be randoml…

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This early-phase trial is testing a new immunotherapy drug called xaluritamig combined with standard hormone therapies (darolutamide or abiraterone) in 60 men with metastatic hormone-sensitive prostate cancer. The main goal is to check safety and tolerability, while also looking …

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This study tests a drug called REGN5678 in men with high-risk prostate cancer who will later have their prostate removed. The goal is to check the drug's safety and how it affects the cancer before surgery. About 42 men will take part in this early-phase trial at MD Anderson Canc…

This early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the …

This study tests a new drug called AZD2265, which delivers radiation directly to prostate cancer cells. It is for people with a type of advanced prostate cancer that no longer responds to hormone therapy. The trial compares the new drug to standard treatments to see if it can slo…

This study is for men with prostate cancer that has spread to a few other parts of the body at diagnosis. It tests whether adding radiation therapy directly to those cancer spots (called metastasis-directed radiotherapy) can help keep the cancer under control longer than the usua…

This phase II trial tests whether adding bipolar androgen therapy (cycles of testosterone) to the standard Sipuleucel-T vaccine can boost the immune response in men with metastatic castration-resistant prostate cancer. About 26 participants will receive both treatments, and resea…

This early-phase study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This Phase 3 trial tests whether adding the experimental drug mevrometostat to the standard drug enzalutamide can slow cancer growth better than enzalutamide alone. It involves 900 men with metastatic castration-resistant prostate cancer who have not yet tried certain hormone the…

This study tests a new robot-assisted surgery for localized prostate cancer that leaves the full length of the urethra intact. The goal is to help men regain urinary continence faster after prostate removal. About 60 men with early-stage prostate cancer will undergo the procedure…

This study tests whether adding darolutamide to standard treatments can help men with a certain type of advanced prostate cancer (mCRPC) live longer without their cancer getting worse. About 162 participants will receive either standard care alone or standard care plus darolutami…

This study compares two radiotherapy schedules for men whose prostate cancer has returned after surgery. The standard treatment takes 5 weeks, while the shorter one takes 4 weeks. Researchers want to see if the shorter schedule causes no more side effects and controls the cancer …

This study is testing two experimental drugs (AZD9574 and AZD2265) together in people with metastatic prostate cancer that has spread beyond the prostate. The goal is to see if the combination is safe and can shrink tumors or lower PSA levels. About 152 adults whose cancer has no…

This trial tests whether focal ablation—using extreme cold (cryotherapy) or high-intensity ultrasound (HIFU)—can effectively destroy prostate tumors while leaving healthy tissue unharmed. It enrolls men with early-stage, localized prostate cancer that shows up on MRI. The goal is…

This study tests whether adding the experimental drug mevrometostat to the standard treatment enzalutamide can slow down cancer growth better than enzalutamide alone. It involves 1000 men with metastatic prostate cancer that still responds to hormone therapy. Participants will be…

This study tests a new drug called GVV858, alone or with hormone therapy, in people with advanced hormone receptor-positive, HER2-negative breast cancer and other solid tumors. The goal is to find the safest dose and see how well it works. About 205 adults whose cancer has progre…

This early-stage study tests BPX-601, a personalized CAR T cell therapy made from a patient's own immune cells, for advanced prostate cancer that has spread and stopped responding to other treatments. The trial will enroll 36 people to find the safest dose and check for side effe…

This study tests whether adding targeted radiation or heat-based ablation to ongoing drug therapy can control genitourinary cancers (prostate, bladder, or kidney) that have started growing in only a few new areas. Participants continue their current systemic treatment while recei…

This study tests a personalized approach to radiation therapy for men whose prostate cancer has returned after surgery. Instead of giving everyone the same treatment, doctors will adjust the plan based on how well the cancer responds to initial radiation. Those who respond well m…

This study tests whether early referral to a cardio-oncology specialist can lower heart risks in prostate cancer patients receiving long-term hormone therapy (ARPI). About 80 men with high-risk or advanced prostate cancer and additional heart risk factors will be assigned to eith…

This study tests a high-dose radiation implant (brachytherapy) for men whose prostate cancer returned after standard external beam radiation. About 30 participants will receive this targeted treatment to the exact spot of recurrence, identified by advanced MRI. The goal is to con…

This phase 2 study tests an oral drug called XL092 (Zanzalintinib) in 32 men with metastatic castration-resistant prostate cancer that has worsened after treatment with Lu-PSMA-617. Participants take one tablet daily at home. The main goal is to see how many men have their cancer…

This study tests a program designed to help men with prostate cancer manage their heart health while undergoing hormone therapy (ADT). The program involves two counseling sessions with a nurse or physician assistant to educate about cardiovascular risks and how to reduce them. Re…

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It compares a new targeted drug, ifinatamab deruxtecan, to standard chemotherapy (docetaxel) to see which helps people live longer a…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get …

This phase 3 trial compares a new drug, BMS-986365, against standard treatments (docetaxel or other hormone therapies) in 960 men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The main goal is to see if the new drug delays ca…

This Phase 3 trial tests whether personalizing apalutamide treatment based on cancer aggressiveness can reduce fatigue and other side effects in men with prostate cancer who have detectable PSA after prostatectomy. About 120 participants will receive either standard therapy or a …

This study tests whether a new cell therapy called STEAP1 CAR T, given together with the hormone drug enzalutamide, is safe and effective for men with metastatic castration-resistant prostate cancer (mCRPC). The therapy uses a patient's own immune cells, modified in the lab to be…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This study tests an experimental oral drug called HLD-0915 in men with metastatic prostate cancer that has worsened after other treatments. The trial has two phases: Phase 1 checks safety and the best dose, while Phase 2 looks at how well it controls the cancer. About 190 men wil…

This study tests a new drug called BNT324 against standard chemotherapy (docetaxel) in men with metastatic castration-resistant prostate cancer that has progressed after hormone therapy. The goal is to see if BNT324 helps patients live longer without their cancer worsening. About…

This phase 2 trial tests whether giving prostate cancer radiation in just 2 sessions is as safe and effective as the standard 5-session approach. About 100 men with low- or intermediate-risk prostate cancer will be randomly assigned to one of the two schedules. Both groups will u…

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This study tests a new drug called tulmimetostat combined with standard hormone therapies (darolutamide or abiraterone) in men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination is safe and works better than standard ca…

This study tests a new treatment called SYNC-T therapy (SV-102) for men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 91 me…

This study tests a special scaffold placed during prostate removal surgery to help men regain bladder control. About 266 men will be randomly assigned to get the scaffold or standard care. The goal is to see if the scaffold reduces urine leakage and improves quality of life over …

This study tests whether adding the drug niraparib to standard hormone therapy after radiation helps control high-risk prostate cancer that hasn't spread far. About 200 men will receive either hormone therapy alone or hormone therapy plus niraparib. The goal is to see if the comb…

This study compares a new, shorter radiation treatment (5 sessions over 2 weeks) to the standard longer course (20-45 sessions over 4-9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter approach works just as well at preventing the cancer from sprea…

This study is testing a new treatment called 4SCAR-PSMA T cells for people whose cancers have a specific marker called PSMA. The therapy involves collecting a patient's own immune cells, modifying them to better recognize and attack cancer cells, and infusing them back. Up to 100…

This study tests a new drug called AZD9750, alone or with another drug (saruparib), in 300 men with metastatic prostate cancer that has progressed despite standard treatments. The goal is to check safety, find the right dose, and see if it can lower PSA levels, a marker of cancer…

This study tests a new drug called tinengotinib combined with standard hormone therapies (abiraterone or enzalutamide) in 50 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to usual treatment. The goal is to see if the combination i…

This study tests a new combination of two drugs (tulmimetostat and JSB462) in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The trial has two parts: first, finding the safest dose, then comparing the combination to usual car…

This study tests a radioactive drug called lutetium Lu 177 dotatate in men with advanced prostate cancer that has neuroendocrine features. The drug seeks out and kills cancer cells that have a specific protein on their surface. The goal is to see if it can shrink tumors. About 35…

This study tests whether taking darolutamide (a hormone-blocking pill) plus standard hormone therapy for 12 or 24 weeks before prostate removal surgery can reduce or eliminate cancer in men with high-risk localized prostate cancer. About 250 men in China will be randomly assigned…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This study tests if men with metastatic hormone-sensitive prostate cancer who have a strong initial response to hormone therapy can safely take breaks from one of their medications (relugolix) to reduce fatigue. About 160 participants will either continue standard daily therapy o…

This study compares two treatments for low-to-intermediate risk prostate cancer: a new robotic surgery that removes part of the prostate through a single small incision, and high-intensity focused ultrasound (HIFU) that uses sound waves to destroy cancer cells. About 276 men will…

This study tests a new treatment called 4SCAR-CD44v6 T cells for people with cancers that have a specific protein called CD44v6. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The trial will enroll 100 participants to check sa…

This study tests a new drug called REGN5678, given alone or with another drug (cemiplimab), in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the combination can safely shrink tumors by helping the immune system attack cancer c…

This phase 3 trial is testing whether adding the experimental drug xaluritamig to standard abiraterone helps men with metastatic castration-resistant prostate cancer live longer. About 750 participants who have not yet had chemotherapy will be randomly assigned to receive either …

This study tests a new way to deliver high-dose radiation to prostate tumors using real-time MRI guidance. It includes two groups: men whose prostate cancer has returned after prior radiation, and men with advanced cancer receiving standard external beam radiation plus this boost…

This early-stage trial tests a new drug called 177Lu-PSMA-VG01 in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has spread and stopped responding to hormone therapy. The drug is designed to deliver radiation directly to cancer cells, aiming to sh…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This early-stage trial tests a new treatment made from a patient's own immune cells (TILs) for metastatic colorectal or prostate cancer. The goal is to see if repeated doses are safe and feasible in 12 participants. The therapy aims to help the immune system fight cancer, but ong…

This early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding …

This study tests proton radiation therapy for men with prostate cancer that has returned or is at risk of returning after prostate removal surgery. Researchers want to see if this precise type of radiation can control the cancer while causing fewer side effects than standard radi…

This phase 2 trial tests a two-step treatment for men with metastatic prostate cancer that no longer responds to standard hormone therapy. First, patients receive a combination of testosterone and an experimental drug called ZEN-3694, followed by a mix of enzalutamide and ZEN-369…

This Phase 3 trial tests whether adding a targeted radiation drug (lutetium-177 rosopatamab) to standard care can help men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The study will enroll 520 men across multiple countries. Par…

This Phase 3 trial tests whether adding the chemotherapy drug docetaxel to the standard treatment (apalutamide plus hormone therapy) can help men with metastatic hormone-sensitive prostate cancer who did not have a strong initial response to apalutamide alone. About 320 men will …

This phase II trial is testing a focused, high-dose radiation therapy (SBRT) given in just two sessions for men with early-stage prostate cancer that hasn't spread. The goal is to see if this approach can destroy the tumor while avoiding the side effects of treating the whole pro…

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-phase trial tests a new drug, GSK5458514, designed to help the immune system attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The study will first find a safe dos…

This study tests a drug called tarlatamab in people with a specific type of advanced prostate cancer (DLL3-positive) that has spread and either came back or didn't respond to prior treatments. About 32 participants will receive the drug to see if it can shrink tumors or slow the …

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This Phase III trial is testing whether using PET scans to guide treatment can help men whose prostate cancer has returned after surgery. For those without signs of spread outside the pelvis, researchers are adding a drug called apalutamide (plus other hormones) to standard radia…

This early-phase trial is testing a new drug called GSK5471713 in 54 men with metastatic castration-resistant prostate cancer that has worsened despite standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors or lower PSA levels. It is the fir…

This study tests whether adding the drug saruparib to standard radiation and hormone therapy can delay the spread of cancer in 700 men with high-risk prostate cancer that has a BRCA gene mutation. Participants will receive either saruparib or a placebo alongside their usual treat…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This study tests whether adding an experimental drug called PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread to other parts of the body. About 86 men with either castration-sensitive or castration-resistant metastatic prostate cancer…

This study tests a new drug called IDE574 in people with advanced solid tumors or a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study has two parts: first, testing IDE574 alone in various cancers; second, combining it…

This study tests whether curcumin, a natural compound found in turmeric, can slow or stop the progression of low-risk prostate cancer in men who are not receiving immediate treatment. About 291 men with early-stage prostate cancer will take either curcumin or a placebo daily for …

This phase 2 trial is testing three different drugs—abiraterone acetate, enzalutamide, and apalutamide—in 192 veterans with castrate-sensitive prostate cancer that has spread. The goal is to see which drug works best as a first treatment when combined with hormone therapy. Resear…

This study compares a new boost approach called irreversible electroporation (IRE) using the NanoKnife system against the standard radiation boost for men with intermediate-risk prostate cancer. All participants will receive standard stereotactic body radiation therapy (SBRT), bu…

This study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…

This study tests whether the drug talazoparib, given alone or with enzalutamide, can slow down cancer growth in men with a certain type of advanced prostate cancer that has stopped responding to a previous treatment called abiraterone. About 126 participants with specific gene ch…

This study tests an experimental drug called AZD8359 for men with metastatic prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to guide the body's immune cells to attack cancer cells. The trial will first find the safest dose…

This study tests whether a new type of radiation seed, called DaRT, can be safely placed inside the prostate to treat cancer that has returned after initial treatment. Up to 10 men with non-metastatic, locally recurrent prostate cancer will receive the seeds. The main goal is to …

This Phase 3 trial is testing whether adding pelvic radiotherapy to standard hormone therapy can delay cancer progression in men whose prostate cancer has spread to nearby lymph nodes after prostate removal surgery. About 372 participants will be randomly assigned to receive eith…

This study tests whether giving radiation to the para-aortic lymph nodes (located in the abdomen) can better control prostate cancer that has returned in a limited number of spots. Men with hormone-sensitive prostate cancer and up to five lesions seen on a PSMA PET/CT scan will r…

This phase 2 trial tests a combination of hormone therapy (Lupron), an androgen blocker (Darolutamide), and an immunotherapy (Pembrolizumab) given before and after prostate removal surgery in 40 men with high-risk prostate cancer. The goal is to see if this approach can reduce or…

This study tests darolutamide, a drug that blocks male hormones fueling prostate cancer, in Indian men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). All 50 participants will take darolutamide pills twice a day along with standard hormone therapy. Th…

This phase 2 trial is testing whether combining focal prostate ablation (a surgery that destroys only the cancerous part of the prostate) with a short course of hormone therapy can effectively treat intermediate-risk prostate cancer. The study will enroll 57 participants and meas…

This early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA…

This phase 2 trial is testing a drug called ivonescimab in 24 people with advanced cutaneous squamous cell carcinoma (a type of skin cancer) or castration-resistant prostate cancer. The goal is to see if the drug can help control the cancer and to check for side effects. Particip…

This study tests a new drug called AZD0516, given alone or with other cancer drugs, in people with metastatic prostate cancer that has spread. The main goals are to check safety, find the best dose, and see early signs of tumor control. About 177 participants will take part acros…

This registry tracks 2,500 men with prostate cancer who receive Vanquish therapy, a procedure that uses water vapor (steam) to destroy cancerous tissue. The goal is to see how well it controls the disease and what side effects occur over time in real-world settings. Participants …

This study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must alread…

This study is testing a new type of radiation therapy for early-stage prostate cancer that delivers very high doses in just a few sessions. The radiation machine adjusts the beam daily based on the patient's anatomy, aiming to protect healthy tissue. Researchers will track qualit…

This early-stage study tests a new treatment called ETB-DualNK-01 for men with advanced prostate cancer that has stopped responding to hormone therapy. The treatment uses donor immune cells (NK cells) that are engineered to target two cancer markers, PSMA and PSCA. The study aims…

This study tests a procedure called irreversible electroporation (IRE) using the NanoKnife system to treat intermediate-risk prostate cancer. The goal is to destroy cancer cells with fewer side effects than standard treatments like surgery or radiation. About 100 men over age 50 …

This study tests a new treatment for people with metastatic breast or prostate cancer that has stopped responding to standard therapies. Participants receive infusions of their own immune cells that have been armed with a special antibody to help them find and attack cancer cells…

This early-phase study tests a new combination of two drugs that deliver radiation directly to prostate cancer cells. The goal is to find the safest dose that can be given together. About 42 men with advanced prostate cancer that has stopped responding to hormone therapy will tak…

This study tests a new oral drug called pocenbrodib, alone or with another drug (darolutamide), in 120 men with metastatic castration-resistant prostate cancer (mCRPC). The goal is to find safe doses and see if the combination can slow cancer growth. It is an early-stage trial, s…

This study tests a new drug, JSB462, combined with standard therapy (abiraterone) in 150 men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination lowers PSA levels more effectively and delays cancer growth. Participants w…

This early-stage study tests a treatment called bipolar androgen therapy for men with advanced prostate cancer that no longer responds to standard hormone therapy. The treatment involves raising and lowering testosterone levels in a controlled way to try to slow cancer growth. Th…

This Phase 3 trial tests whether adding a radioactive drug called AAA817 to standard hormone therapy can slow cancer growth better than current treatments alone. About 940 men with PSMA-positive metastatic castration resistant prostate cancer will be randomly assigned to receive …

This study tests a new drug called HRS-5041, taken as a pill, combined with other cancer treatments for men with advanced prostate cancer. The goal is to see if the combination is safe and helps control the cancer. About 100 men aged 18 to 80 will take part. The study is currentl…

This study is tracking 238 adults who are already scheduled to have a procedure for kidney stones or an enlarged prostate (BPH) using Boston Scientific devices. The main goal is to see how often serious side effects happen with these tools in real-world use. Researchers will also…

This phase 3 trial is testing whether adding the chemotherapy drug docetaxel to standard hormone therapy (ADT plus an ARPI) can lower the chance of prostate cancer growing or spreading. The study enrolls 830 men with metastatic prostate cancer that is sensitive to hormone therapy…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This phase 2 study is testing whether adding talazoparib to standard hormone therapy and enzalutamide can help men with prostate cancer that has spread to lymph nodes. About 30 participants will take the drug combination before having their prostate removed. The goal is to see if…

This phase 3 trial tests a radioactive drug called lutetium-177 vipivotide tetraxetan in 450 men whose prostate cancer has returned and spread to a few spots after initial treatment. The drug targets a protein on cancer cells and delivers radiation directly to them. The goal is t…

This early-phase trial tests a new drug that delivers radiation directly to cancer cells carrying a specific protein called GRPR. The study includes 48 adults with advanced cancers like prostate, breast, lung, or colon cancer that have not responded to standard treatments. The ma…

This early-phase trial is testing an experimental drug called CX-5461 (Pidnarulex) in people with advanced solid tumors (pancreatic, prostate, breast, or ovarian) that have specific BRCA2 or PALB2 gene mutations. The main goal is to find a safe and tolerable dose for future studi…

This study is testing a new drug called ADI-PEG20, which breaks down arginine (a nutrient cancer cells need), together with two chemotherapy drugs (carboplatin and cabazitaxel) in men with aggressive variant prostate cancer. The goal is to find the safest dose and check for side …

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard treatments (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that got worse after one prior hormone therapy. The goal is to s…

This study tests a procedure called TULSA that uses MRI images to guide high-energy ultrasound waves to destroy prostate cancer tumors. About 21 adults with early-stage prostate cancer that shows up on MRI will receive this heat-based treatment. The goal is to see if the approach…

This study tests an experimental drug called AZD6621 for men with metastatic prostate cancer that has spread. The drug is designed to help the body's immune cells attack cancer cells. The trial has two parts: first, finding the safest dose, then testing that dose in more people t…

This study tests whether high intensity focused ultrasound (HIFU) can control prostate cancer that has come back after radiation therapy. About 25 men will receive one session of HIFU using the Focal One device. Researchers will check if the cancer remains absent in the treated a…

This early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has stopped responding to hormone treatment. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or lower PSA levels. …

This phase II trial is testing whether adding two hormone-blocking drugs, relugolix and enzalutamide, to standard radiation therapy can better control very-high-risk prostate cancer. About 50 men will receive the combination for 18 months. The main goal is to see if it lowers the…

This phase 2 trial is testing whether the immunotherapy drug atezolizumab, alone or combined with etrumadenant or tocilizumab, can boost immune cell activity in prostate tumors before surgical removal. About 68 men with localized prostate cancer will receive treatment before radi…

This early-phase trial is testing a combination of two experimental drugs—Pasritamig and ARX517—in 140 men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The goal is to find a safe dose and see if the combin…

This Phase 3 trial tests whether adding pasritamig, a drug that directs the body's T-cells to attack prostate cancer cells, to standard chemotherapy (docetaxel) can slow cancer growth better than chemotherapy alone. The study involves 800 men with metastatic castration-resistant …

This study is testing a new way to give radiation for high-risk prostate cancer that has not spread. One hundred men will receive a shorter, stronger radiation boost to the prostate along with standard pelvic radiation. The goal is to see if this approach is safe and does not cau…

This study tests a new treatment called AB-3028, which uses a patient's own immune cells (T cells) that have been modified in a lab to better attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a type that has stopped responding to ho…

This study looks at men whose prostate cancer has spread to a few spots in the body (oligometastatic). It compares standard radiation and hormone therapy alone versus adding the drug abiraterone for 8-9 months. The goal is to see if the extra drug improves quality of life and del…

This study tests a new drug called INV-9956 in 84 men with advanced prostate cancer that has spread and stopped responding to hormone therapy and chemotherapy. The goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. Participants take INV-9956 al…

This early-phase study tests a new combination of two drugs for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The first drug helps the immune system attack cancer cells, and the second aims to make the immune system work bet…

This early-phase study is testing a new drug called pasritamig (JNJ-78278343) combined with other treatments for men with metastatic prostate cancer that no longer responds to hormone therapy. The goal is to find the safest and most effective dose. About 300 participants will be …

This phase 3 study tests a drug called pasritamig, which helps the body's immune T-cells attack prostate cancer cells. The trial includes 663 men with metastatic castration-resistant prostate cancer, a stage where standard hormone therapy no longer works. Participants receive eit…

This study tests a new way to deliver radiation therapy for early-stage prostate cancer. Instead of two separate sessions days apart, both radiation doses are given just three hours apart on the same day. The goal is to see if this is safe and could make treatment more convenient…

This study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if the combination can stop or shrink tumors. Participants must have non-measurable disease o…

This early-phase study tests two experimental drugs (JNJ-87189401 and JNJ-78278343) that help the immune system attack prostate cancer cells. The study involves about 355 men with advanced prostate cancer. The main goal is to find the safest dose and check for side effects.

This study follows 700 adults with prostate cancer who have already received at least one dose of lutetium-177 PSMA-617 in earlier Novartis trials. Researchers will monitor long-term side effects such as dry mouth, eye dryness, bone marrow problems, kidney damage, and new cancers…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This study tests a laser treatment guided by MRI to destroy early-stage prostate cancer in men aged 40-80 with low to intermediate risk. The goal is to control the cancer and avoid more aggressive treatments like surgery or radiation. Researchers will check results with follow-up…

This study tests whether a new combination of two drugs, inavolisib and enzalutamide, works better than standard treatments for men with metastatic castration-resistant prostate cancer that has progressed after one prior therapy. About 100 men will be randomly assigned to receive…

This study looks at whether metformin, a drug used for diabetes, can help prostate cancer patients who have high blood sugar or are overweight. About 100 men will either take metformin plus get lifestyle advice, or just get lifestyle advice. The main goal is to see if it's possib…

This study tests a next-generation radiation therapy (SABR) for men with low to high-risk prostate cancer. The goal is to see if this advanced technique can control the cancer while reducing long-term side effects like urinary and bowel problems. About 136 participants will recei…

This study tests whether taking creatine supplements along with a home-based resistance training program can help men with metastatic prostate cancer maintain muscle mass and reduce fatigue. Two hundred participants will be randomly assigned to receive either creatine or a placeb…

This early-phase study tests a new radioactive drug (161Tb-PSMA-I&T) in 12 Taiwanese men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The drug seeks out prostate cancer cells and delivers targeted radiation. The main goal is…

This study tests several new drug combinations for men with advanced prostate cancer that has spread. The experimental drugs include QLC5508 (a targeted therapy that delivers a toxin to cancer cells) and QLH12016 (a drug that breaks down the male hormone receptor). These are comb…

This early-phase trial is testing a new treatment called A-CAR032 for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack cancer …

This study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control PSA levels in men whose prostate cancer has returned after initial treatment. About 65 participants will receive either enzalutamide alone or both drugs for 3 months, wit…

This study tests whether freezing only the part of the prostate that contains cancer (focal cryotherapy) can control intermediate-risk prostate cancer. About 30 men with a single area of cancer will receive this targeted treatment. The goal is to reduce side effects while keeping…

This study tests whether analyzing a patient's tumor DNA and RNA can help doctors select the most effective treatment for advanced prostate cancer that no longer responds to hormone therapy. About 474 participants will receive one of several drugs based on their genetic profile. …

This early-phase study tests whether combining a radioactive drug (177Lu-PSMA-617) with liver-directed procedures (ablation or chemoembolization) is safe for men with metastatic castration-resistant prostate cancer that has spread to the liver. The 30 participants must have alrea…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This study tests a new drug combination (SX-682 plus enzalutamide) in 53 men with metastatic castration-resistant prostate cancer that has worsened despite prior treatments. The goal is to see if the combination can shrink tumors, lower PSA levels, or keep the cancer stable for a…

This study tests whether adding precise, high-dose radiation to cancer spots outside the prostate (called metastases) can help men whose prostate cancer has spread to just a few places. About 122 men with up to 5 metastatic spots will receive standard treatment plus either observ…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This study follows 500 men in Germany with metastatic hormone-sensitive prostate cancer (mHSPC) who are taking darolutamide plus standard hormone therapy. Researchers will check how many have very low PSA levels after 12 months and track survival and health over 5 years. The goal…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This early-stage study tests a new drug called AMG 509, alone or with other medicines, in people with a type of advanced prostate cancer that no longer responds to hormone therapy. The main goals are to check safety and how the body processes the drug. About 479 participants will…

This Phase II trial tests two experimental drugs, JS212 and JS213, alone or together, in 410 adults with advanced solid tumors (kidney, prostate, bladder, or skin cancer). The main goal is to see if the drugs shrink tumors. Researchers will also check safety and how long any bene…

This study tests a new drug called TRC003 for men with a type of advanced prostate cancer that has spread and is no longer responding to hormone therapy or chemotherapy. TRC003 is a radioactive molecule designed to attach to prostate cancer cells and deliver radiation directly to…

This study tests a new drug called TD001 in men with a type of advanced prostate cancer that has stopped responding to hormone therapy. TD001 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to prostate cancer cells that have a specific marker (…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This trial is testing a daily adaptive radiation therapy for low to intermediate risk prostate cancer that spares the urethra. The goal is to reduce urinary side effects compared to standard radiation. About 132 participants will receive this tailored radiation, and their urinary…

This early-stage trial tests a new oral drug called INR731, alone or with standard hormone therapy drugs, in 208 men with metastatic prostate cancer that no longer responds to hormone treatment. The main goals are to check safety, find the right dose, and see if the drug shows an…

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This early-phase trial is testing a new radioactive drug called FL-020 in 50 men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. The drug is designed to seek out and deliver radiati…

This trial is testing whether combining the drug Pluvicto with precise radiation (SBRT) can lower the chance of cancer returning in men with locally advanced prostate cancer, while also reducing the need for long-term hormone therapy. About 45 participants will receive one to thr…

This study tests an experimental drug called AAA817 in adults with a specific type of advanced prostate cancer (PSMA-positive) that has worsened after prior treatments, including a targeted therapy. About 443 participants will be randomly assigned to receive either AAA817 or the …

This clinical trial is testing an experimental drug called opevesostat (MK-5684), either alone or combined with other cancer drugs, in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The study involves 220 participants and has t…

This early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…

This study tests a precise radiation treatment (MR-guided high-dose-rate brachytherapy) for men whose prostate cancer has returned in the prostate bed after previous radiotherapy. About 20 participants will receive this targeted therapy to see if it can control the cancer with ac…

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …

This phase 2 trial tests a drug called FG-3246, which is designed to seek out and attack prostate cancer cells that have a specific marker (CD46) on their surface. The study will enroll 75 men with metastatic castration-resistant prostate cancer that has worsened after hormone th…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This trial tests a type of internal radiation called high-dose-rate brachytherapy for men with early-stage prostate cancer. The goal is to see if focusing radiation only on the tumor can control the cancer while causing fewer urinary and sexual problems than standard treatments. …

This early-stage trial tests an oral drug called DS9051b in 40 people with advanced adrenocortical carcinoma or metastatic castration-resistant prostate cancer. The main goal is to check safety and find the right dose, while also looking for any signs that the drug might shrink t…

This early-stage trial is testing a new oral drug called DCC-2812 in 60 people with advanced kidney, bladder, or prostate cancers that have spread. The main goals are to check safety and find the right dose, while also looking for signs that the drug can shrink tumors. It is a fi…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tr…

This study tests a new radioactive drug (lutetium rhPSMA-10.1) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose, and to see if it can shrink tumors or lower PSA levels. About 82 …

This study tests a new two-step approach for men with advanced prostate cancer that has stopped responding to standard hormone therapy. First, patients receive a high dose of testosterone, followed by a targeted radioactive drug. The goal is to see if this combination is safe and…

This early-stage trial tests whether adding valemetostat to the standard drug darolutamide is safe and tolerable for men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. About 60 adu…

This early-stage trial is testing a drug called xaluritamig, given alone or with a hormone blocker, before men with intermediate- or high-risk prostate cancer have their prostate removed. The main goal is to see if the treatment is safe and does not interfere with surgery. About …

This study tests a mix of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) in people with advanced solid tumors or prostate cancer that has come back. The goal is to find the safest dose and see if the combination can stop the cancer from grow…

This study tests whether a precise type of radiation (SBRT) alone can control unfavorable intermediate-risk prostate cancer, avoiding the need for hormone therapy. About 215 participants will receive SBRT, with the radiation dose guided by a genetic test (Decipher) to personalize…

This study tests whether testosterone replacement therapy (TRT) is safe and beneficial for men with low testosterone and early-stage prostate cancer who are on active surveillance. Researchers will track cancer progression, quality of life, and whether men stay on active surveill…

This phase 2 trial tests whether a daily supplement called urolithin A can lower oxidative stress in prostate tumors. Ninety men with prostate cancer will take either urolithin A or a placebo for 3 to 6 weeks before their prostate removal surgery. The main goal is to see if the s…

This early-stage study tests a new drug (AZD2284) that delivers radiation directly to prostate cancer cells. It is for men whose cancer has spread and no longer responds to hormone therapy. The main goals are to check safety and find the right dose, while also measuring how well …

This study looks at men with high-risk prostate cancer that appears on only one side of the prostate. During robotic surgery to remove the prostate, doctors will either remove lymph nodes from both sides of the pelvis or just the side with cancer. The goal is to see if removing f…

This study tests whether adding a short, 30-day course of the oral hormone drug Relugolix to standard targeted radiation (SBRT) works better than radiation alone for men with intermediate-risk prostate cancer. About 60 men will be randomly assigned to one of the two treatments. T…

This Phase 3 trial compares a new oral drug, rezvilutamide, against the current standard enzalutamide, both combined with hormone therapy, in 206 men with low-volume metastatic prostate cancer that still responds to hormones. The main goal is to see if rezvilutamide can lower PSA…

This study compares a shorter, high-dose radiation treatment (SBRT) to standard radiation for men whose prostate cancer has come back after surgery. About 284 men will be randomly assigned to one of the two approaches. The goal is to see if SBRT is as safe and effective, with few…

This early-stage trial tests a new drug that delivers radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has stopped responding to hormone therapy. The study will check for side effects and see if the drug …

This study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…

This study is testing a procedure called MRI-guided cryoablation, which uses extreme cold to freeze and destroy small prostate cancer tumors. The goal is to see if this targeted approach can safely control the cancer while avoiding the side effects of surgery or radiation. About …

This study tests an internet-based program called iLIVE that combines weight loss coaching and online exercise classes for men who have had hormone therapy for prostate cancer. The goal is to see if it can reduce obesity and frailty, which are common side effects of treatment. Re…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This early-stage trial is testing a new drug called SKB107 in people with advanced solid tumors that have spread to the bones. The drug delivers a small amount of radiation directly to bone tumors. The study will enroll about 90 adults to check if the drug is safe, how it moves t…

This phase 2b trial tests whether adding an experimental drug called ZEN003694 to the standard drug enzalutamide can help men with metastatic castration-resistant prostate cancer that has stopped responding to abiraterone. About 200 men will be randomly assigned to receive either…

This study tests whether a single, very high dose of precisely targeted radiation can safely treat intermediate-risk prostate cancer. About 200 men will receive one 24-Gy dose to the prostate, with a possible extra boost to the main tumor. Researchers will monitor side effects, q…

This trial tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in 60 men with advanced prostate cancer that has spread and stopped responding to other treatments. The drug is designed to attach to prostate cancer cells and destroy them with radiation. The study aim…

This study tests whether eating 2 ounces of walnuts daily for 4-10 weeks can slow prostate cancer growth in 50 men scheduled for prostate removal. Participants are randomly assigned to add walnuts to their usual diet or stick with their normal eating habits. Researchers will meas…

This early-phase trial tests a new two-drug combination for men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The drugs are REGN5678, which helps immune cells target cancer cells, and cemiplimab, which removes the br…

This study compares standard moderate radiation (4 weeks) with shorter, more intense radiation schedules (1-2 weeks or a single session) for treating the prostate in men whose cancer has spread to a few other spots (oligometastatic). The goal is to see if the shorter treatments a…

This phase 3 trial is testing whether taking aspirin and atorvastatin (a common cholesterol-lowering drug) can help men with castrate-resistant prostate cancer live longer. The study plans to enroll 1210 participants who are starting their first treatment for this advanced stage.…

This early-phase trial is testing whether adding ruxolitinib to the standard drug enzalutamide can help men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The study will enroll 20 participants to find the safest dose and check for early s…

This study tests two experimental drugs, REGN4336 and REGN5678, in men with metastatic castration-resistant prostate cancer that has worsened despite prior treatment. The first part finds safe doses, and the second part checks how well the combination shrinks tumors. About 228 pa…

This study tests whether a special 5-day-per-month diet that mimics fasting can improve how well standard prostate cancer treatments work. 138 men with advanced prostate cancer will either follow this diet or eat normally for 6 months. Researchers will measure PSA levels and meta…

This early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…

This study tests if axelopran, a drug used for opioid-induced constipation, can slow tumor growth in people with advanced breast, lung, pancreas, or prostate cancer. About 34 adults whose cancer has worsened after standard treatment will take axelopran daily for up to a year. Res…

This study tests two copper-based drugs that work together: one helps doctors see prostate cancer tumors on scans, and the other delivers targeted radiation to kill them. The trial involves 54 men with a type of advanced prostate cancer that no longer responds to hormone therapy.…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This large Phase 3 trial is testing a new oral drug called opevesostat (MK-5684) against two standard drugs (abiraterone or enzalutamide) in men with metastatic castration-resistant prostate cancer that has worsened after prior hormone therapy and chemotherapy. The study aims to …

This phase 2 trial tests ASP5541, a new injectable form of the hormone therapy abiraterone, in men with advanced prostate cancer that has spread. The study compares ASP5541 (given every 12 weeks) to daily abiraterone pills, both with or without steroids. About 218 men with metast…

This study tests a treatment that uses lasers and a light-sensitive drug to destroy cancer cells in the prostate without major surgery. It is for men whose prostate cancer has returned after radiation therapy and who cannot have surgery or more radiation. The goal is to see if th…

This study tests a low-dose radioactive drug (177Lu-P17-088) that targets a protein called PSMA on prostate cancer cells. It is for people with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The goal is to see if the treatment can …

This early-stage trial tests a new treatment for men with localized prostate cancer. It uses a light-sensitive drug called verteporfin, which is injected into the bloodstream and then activated by laser light delivered through thin fibers placed into the prostate. The goal is to …

This early-stage study tests a new drug, 225Ac-PSMA-Trillium, in people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells to damage them. The main goals are to check safety, find the best …

This study tests whether combining an experimental immunotherapy drug (SHR-1701) with targeted radiation can help men with metastatic castration-resistant prostate cancer, a form that no longer responds to hormone therapy. About 66 participants will receive either the drug plus r…

This study tests a new type of radiation therapy for men with high-risk prostate cancer that hasn't spread. The treatment uses advanced imaging to deliver higher radiation doses directly to the main tumor while also treating the whole pelvis. Researchers want to see if this appro…

This Phase 3 trial tests whether adding darolutamide (Nubeqa) to standard hormone therapy (ADT) helps men with metastatic prostate cancer who are too frail for stronger treatments. About 300 participants will receive either darolutamide or a placebo, plus ADT. The goal is to see …

This study is testing a new, shorter radiation treatment for men with early-stage prostate cancer. Instead of the usual 5 sessions, doctors will give 3 high-dose radiation treatments. The goal is to see if this approach is safe and causes fewer side effects while still controllin…

This trial compares two laser methods (MoLEP and ThuFLEP) for removing prostate tissue in men with enlarged prostates (over 80cc). 120 men aged 40-90 who need surgery will be randomly assigned to one of the two lasers. The main goal is to see which technique is faster, while also…

This early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.…

This early-phase study tests a new drug called DXC008 in people with prostate cancer or other solid tumors (like Ewing sarcoma) who have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Abou…

This phase 2 trial tests whether giving testosterone injections (bipolar androgen therapy) can delay the time it takes for prostate cancer to spread in men whose cancer is progressing despite standard treatment. About 69 men with non-metastatic castrate-resistant prostate cancer …

This study tests whether a high dose of testosterone combined with the chemotherapy drug carboplatin can help men with a specific type of advanced prostate cancer that has stopped responding to standard hormone therapy. About 30 men with a genetic defect called homologous recombi…

This study is for men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. It tests whether adding a targeted radiation drug (225Ac-J591) to immunotherapy (pembrolizumab) and an androgen-receptor inhibitor works better than the im…

This early-phase trial tests an experimental drug called GTB-5550 in adults with advanced solid tumors that have stopped responding to standard treatments. The drug is a nanobody designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. …

This study looks at whether eating a controlled Mediterranean diet before prostate cancer surgery can improve health markers like insulin levels. Twenty men scheduled for prostate removal will receive pre-made meals and be monitored. The goal is to see if this diet is practical a…

This early-stage trial is testing a new biologic drug, JANX014, in 43 men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The main goal is to check safety and find the right dose, while also looking at how the drug moves through th…

This study is testing a new drug called SHR-4394 combined with other anti-cancer treatments for men with prostate cancer. The goal is to find the safest dose and see if the combination can lower PSA levels, a key marker of prostate cancer. About 100 men aged 18 to 85 will take pa…

This study tests whether a special PET-MRI scan using a radioactive tracer called rhPSMA-7.3 can find higher-risk prostate cancer that standard tests might miss. Men with low-risk or favorable intermediate-risk prostate cancer who are candidates for active surveillance will recei…

This trial tests whether a special PET/CT scan using a tracer called POSLUMA can detect prostate cancer in men whose PSA levels are rising after treatment but who had negative results on standard PET scans. The study enrolls men with biochemical recurrence and low PSA levels. Res…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study is testing whether a radioactive tracer called 18F-DCFPyL, used during a PET/CT scan, can better detect where prostate cancer has returned in men whose PSA levels are rising after initial treatment. About 350 men will be followed for up to 5 years with regular scans an…

This study tests a new radioactive tracer called [18F]FluorThanatrace (FTT) used with PET/CT scans to measure PARP-1 activity in men with metastatic prostate cancer. Up to 30 participants will have scans before and after starting a new therapy. The goal is to see if FTT can non-i…

This study tests whether an artificial intelligence (AI) algorithm can help doctors decide where to take biopsy samples in men with prostate MRI findings that are not clearly cancerous. About 50 men with low-risk or uncertain MRI lesions and elevated PSA levels will be randomly a…

This study tests whether men with very high PSA and suspicious MRI can safely skip the painful 12-needle systematic biopsy and rely only on targeted samples. Over 1,200 men will get both biopsies, but each sample is analyzed separately to see how often the extra needles find dang…

This phase 2 trial is testing whether a special PET scan tracer called 18F-DCFPyL can accurately show how prostate cancer responds to standard radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will receive the tracer and undergo PET/CT scans at s…

This study investigates whether a blood test (liquid biopsy) can detect prostate cancer early by looking for tumor cells and genetic material in the blood. Researchers will compare blood samples from men with suspected prostate cancer to those without the disease. The goal is to …

This early-stage trial tests whether a special nanoparticle tracer can help surgeons see prostate cancer cells during surgery. Sixteen men with high-risk prostate cancer will receive an injection of the tracer, then undergo PET/MRI scans and surgery. The goal is to see if the tra…

This early-stage study tests a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal is to see if it is safe and can help detect cancer that has spread or come back. Participants receive one injection and then undergo PET scans to measure rad…

This study tests a new imaging method called FAPI PET/MRI to see if it can find and track prostate cancer that has spread better than current scans. About 30 adults with prostate cancer will get two research scans. The goal is to improve how doctors detect and monitor the disease…

This study tests a new imaging approach for people with advanced breast or prostate cancer. It uses two radioactive tracers to find tumors that have a specific protein (GRPR). The goal is to see if this method is safe and can help doctors see where the cancer is in the body. Abou…

This study tests whether a newer biopsy method (perilesional biopsy) can find aggressive prostate cancers as well as the standard combination of targeted and systematic biopsies. About 640 men with a single suspicious MRI lesion will be randomly assigned to one of two biopsy appr…

This study is testing a blood test called Proclarix to see if it can better identify men with aggressive prostate cancer before they have a biopsy. About 500 men aged 40-75 with certain PSA levels will give a blood sample before their scheduled biopsy. The test results will be co…

This study compares two biopsy methods in 572 men who have multiple suspicious spots on MRI but have never had a prostate biopsy. One method combines targeted biopsy with a wider sampling around each spot (perilesional biopsy), while the other combines targeted biopsy with standa…

This study at Mayo Clinic is testing whether a special ultrasound technique called vibroelastography can better assess erectile function recovery in men after prostate cancer surgery. The technique measures tissue stiffness, which may indicate scarring. Ten men with low-risk pros…

This study tests whether combining two advanced imaging techniques (micro-ultrasound and MRI) during prostate biopsy can find more aggressive cancers than the current standard approach. About 400 men with suspected prostate cancer will participate. The goal is to improve detectio…

This study tests a new type of PET/CT scan using a radioactive tracer called copper Cu 64 PSMA I&T to see if it can accurately find prostate cancer that has spread to pelvic lymph nodes. About 439 men with newly diagnosed, aggressive prostate cancer who are planning to have their…

This study compares a newer PSMA PET scan to the standard MRI for staging prostate cancer in men eligible for focal therapy (treatment that targets only the tumor). About 138 men with early-stage prostate cancer will be randomly assigned to get the PSMA PET scan or not. The goal …

This phase 2 trial tests whether a radioactive tracer called 64Cu-DOTA-AE105 can accurately show the aggressiveness of prostate cancer on a PET scan. About 168 men with low- to intermediate-risk prostate cancer will receive the tracer and undergo imaging. The goal is to see if th…

This study is testing whether an artificial intelligence (AI) model can accurately predict which prostate cancers are aggressive and need treatment. Researchers will combine MRI and ultrasound images with tissue samples from 3,000 men. The goal is to reduce unnecessary biopsies a…

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This study tests whether using a special scan (PSMA PET/MRI) to guide prostate biopsies can find cancers that standard methods miss. It includes 230 men with elevated PSA, at least one prior negative biopsy, and low-risk MRI results. The goal is to improve early detection of clin…

This study is testing whether new MRI techniques and artificial intelligence can improve how doctors diagnose prostate cancer. Researchers will enroll 275 men with suspected or confirmed prostate cancer. The goal is to make diagnosis more accurate and less invasive than current m…

This study tests a new microscope called LaserSAFE that scans the removed prostate during surgery to see if cancer cells are at the edge. If it works well, surgeons can decide right away whether to spare nearby nerves. About 693 men with prostate cancer will take part, and the st…

This phase 3 trial tests a new radioactive imaging agent, 64Cu-SAR-bisPSMA, to see if it can better detect prostate cancer that has spread to nearby lymph nodes. About 383 men with high-risk prostate cancer will receive a single injection of the agent before their scheduled prost…

This study is testing whether a special PET scan using flotufolastat F 18 can detect prostate cancer that has come back after surgery, even when PSA levels are very low (0.20 ng/mL or less). Researchers will scan 50 men with a history of prostate cancer and a rising PSA after pro…

This study is testing whether a special type of PET/CT scan (PSMA-PET CT) can accurately detect aggressive prostate cancer in men who are on active surveillance (watchful waiting). Researchers will scan 200 men with low- or favorable intermediate-risk prostate cancer at the start…

This study tests two advanced imaging techniques, PSMA PET/CT and MRI-RSI, against the standard MRI to see which finds and outlines prostate tumors most accurately. Fifty men with newly diagnosed, higher-risk prostate cancer will undergo all scans and a targeted biopsy. The goal …

This study tests a special dye that makes prostate cancer cells glow during surgery. About 22 men with aggressive prostate cancer will receive the dye before their prostate removal surgery. Surgeons will use a special camera to see the glowing cancer, helping them remove more of …

This study is testing a new type of PET/CT scan that targets a protein called ACP3 to find prostate cancer tumors. Researchers will compare it to standard PSMA/FDG scans in 100 adults with newly diagnosed or recurrent prostate cancer. The goal is to see if the ACP3 scan is more a…

This early-phase trial is testing whether a special MRI scan, using hyperpolarized pyruvate and urea, can better detect high-grade prostate cancer that is still confined to the prostate. About 80 men scheduled for prostate removal will receive an IV of these substances before ima…

This early study tests a new radioactive tracer called 68Ga-FC516 in 10 healthy adults and people with prostate cancer. The goal is to see if it is safe and how well it finds tumors on PET/CT scans compared to existing tracers. The results will help improve prostate cancer diagno…

This study is testing new types of MRI scans to see if they can more accurately find and grade prostate cancer without using contrast dye. Researchers will compare these new scans with standard MRI results and tissue samples from surgery or biopsy. About 300 people with suspected…

This study tests a new software tool that automatically analyzes MRI images of the prostate to find cancer areas that doctors might miss. About 180 people with known or suspected prostate cancer will get an MRI and then a targeted biopsy. Researchers will compare the software's a…

This study aims to develop a blood test that detects RNA from tiny particles (exosomes) to predict if prostate cancer has spread to the bones. Researchers will analyze blood samples from 1,000 men with newly diagnosed prostate cancer and compare results with PSMA PET scans. The g…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…

This study tests whether adding tadalafil (a daily pill for erection problems and enlarged prostate) to standard tamsulosin helps men aged 50+ who suddenly can't urinate due to an enlarged prostate. After a catheter is placed, participants take either tamsulosin plus tadalafil or…

This study is for men with low- to intermediate-risk prostate cancer. It compares giving a lower radiation dose to some parts of the prostate versus the same dose to the whole prostate. The goal is to see if the lower dose reduces short-term urinary side effects. About 54 people …

This phase III trial tests whether an automated planning tool called RapidPlan can match or beat human-driven planning for prostate cancer radiation therapy. About 108 men with prostate cancer will be randomly assigned to one of two planning methods. The goal is to see if the aut…

This study compares two procedures for enlarged prostate: water vapor therapy (Rezum) and a special laser technique that aims to preserve ejaculation. 120 sexually active men aged 50+ with moderate-to-severe symptoms will choose their treatment after counseling. The main goal is …

This study compares two minimally invasive procedures for men with an enlarged prostate: water vapor thermal therapy (Rezum) and ejaculation-sparing surgery. It includes 120 sexually active men aged 50 or older who have moderate-to-severe urinary symptoms. The goal is to see whic…

This study tests a device called the Axonics SNM System, which uses mild electrical pulses to calm the nerves that control the bladder. It is for men with overactive bladder, including those with urgency incontinence or frequent urination. The trial will enroll 150 men and track …

This study looks at men over 50 with an enlarged prostate who had a sudden inability to urinate and needed a catheter. All were already taking tamsulosin 0.4 mg daily. The trial compares three options over 7 days: staying on the same dose, doubling it, or switching to silodosin. …

This study tests whether a daily CoQ10 supplement (Ralivia) can improve symptoms of benign prostatic hyperplasia (BPH), such as frequent or difficult urination. One hundred men aged 50–80 with moderate-to-severe BPH will receive either the supplement or a placebo for 3 months. Re…

This study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…

This study looks at whether taking creatine supplements while doing supervised weight training for 12 weeks can help men with prostate cancer who are on hormone therapy (ADT) maintain or improve their muscle mass, strength, and physical function. ADT often causes muscle loss and …

This study tests a web-based program called TEMPO designed to help men with prostate cancer and their caregivers cope with anxiety and improve physical activity. About 376 patient-caregiver pairs will be randomly assigned to use TEMPO or simply monitor their anxiety for 12 weeks.…

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study tests a device called FloStent, a small tube placed in the prostate to help urine flow more easily in men with an enlarged prostate (benign prostatic hyperplasia). About 215 men with moderate to severe symptoms will either get the FloStent or a sham procedure where not…

This study compares two different lasers used during surgery for an enlarged prostate (BPH). The goal is to see which laser reduces bleeding time during the operation. About 180 men will take part, and the results will help surgeons choose the best tool for this common procedure.

This study compares a new, ejaculation-sparing version of standard prostate surgery (HoLEP) for men with enlarged prostates. The goal is to relieve urinary symptoms while preserving the ability to ejaculate normally. Researchers will enroll 48 sexually active men and track ejacul…

This study compares three different surgical techniques for men with very large prostates (over 100 mL) who have severe urinary symptoms. Ninety men will be randomly assigned to receive either thulium fiber laser, holmium laser, or bipolar electrosurgery. Researchers will measure…

This study tests whether a daily CoQ10 supplement (Ralivia) can reduce pain and improve quality of life in men with chronic pelvic pain syndrome. One hundred men aged 18–50 will receive either the supplement or a placebo for 3 months. Researchers will measure changes in pain scor…

This study tests a new surgical technique for men with an enlarged prostate who have not gotten relief from medication. The goal is to improve urination while preserving the ability to ejaculate. Sixty sexually active men will be randomly assigned to either the new ejaculation-pr…

This study tests if a newer, more precise type of radiation (adaptive SBRT) can cause fewer urinary problems than standard radiation for men with localized prostate cancer. About 320 men will be randomly assigned to one of the two radiation methods. The goal is to see if the newe…

This study tests whether a supervised golf exercise program can improve physical function, mental health, and quality of life in prostate cancer survivors who are on hormone therapy. Twenty men aged 55-85 with little or no golf experience will participate. The program includes wa…

This study tests whether applying a powder called ARISTA AH during robotic prostate removal can reduce blood loss and help preserve erectile function. About 362 men with prostate cancer will be randomly assigned to receive the powder or standard care. The goal is to see if the po…

This study tests whether adding acupuncture and acupressure to standard anti-nausea medicine can better reduce chemotherapy-induced nausea. About 90 cancer patients with ongoing nausea will be split into two groups: one gets the extra acupuncture, the other gets medicine alone. T…

This study tests whether a rectal indomethacin suppository given right after surgery can prevent or reduce bladder discomfort caused by a urinary catheter in men undergoing laparoscopic radical prostatectomy. About 130 participants will be randomly assigned to receive either the …

This study looks at whether cooling the mouth with popsicles during chemotherapy can reduce taste changes in prostate cancer patients. About 60 people starting a type of chemo called taxane will be asked to suck on popsicles during their infusion. The goal is to see if this simpl…

This study looks at whether men recovering from robotic prostate surgery can manage pain without automatically receiving opioid painkillers. Half of the 300 participants will get a standard pain plan plus an opioid prescription, while the other half will get only the pain plan an…

This study looks at whether adding local anesthesia (numbing medicine) during a prostate biopsy, while patients are already sedated, reduces pain after the procedure. About 800 men will take part. The goal is to see if this simple change can lower pain scores, cut down on painkil…

This study tests whether wearing a virtual reality (VR) headset during daily radiation therapy can help manage anxiety in people with prostate, breast, lung, or head and neck cancer. About 54 patients will use a Meta Quest 2 headset during their treatments, and researchers will t…

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This study looks at whether saving a small extra artery to the penis during robotic prostate cancer surgery can help men recover erections. About 1 in 3 men have this artery, and the study will use MRI scans to find it before surgery. Researchers will follow 20-40 men for a year …

This study tests an 8-week program where prostate cancer patients and their spouses learn and support each other using a handbook, a mobile app, and professional guidance. The goal is to improve physical symptoms, emotional well-being, and family resilience. Sixty couples will be…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This pilot study is testing a new way to give radiation for prostate cancer that uses an MRI machine to guide the treatment. The goal is to give a lower dose of radiation to the whole prostate while giving a higher dose only to the main tumor, which may reduce side effects like u…

This early study is testing a new, ultra-minimally invasive procedure for men with benign prostatic hyperplasia (BPH) who have significant urinary symptoms. The treatment uses a balloon catheter guided by ultrasound to gently widen the prostate passage. Only 5 men aged 40 to 80 w…

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study tests whether a low to moderate load power training program can improve quality of life, strength, and balance in men with metastatic prostate cancer who are on hormone therapy. About 66 participants will either join a supervised exercise program twice a week for 6 mon…

This study compares two laser surgeries—ThuLEP and HoLEP—for treating enlarged prostate symptoms in men. 150 men will be randomly assigned to one of the two procedures and followed for 12 months. The goal is to see which technique provides better symptom relief, faster recovery, …

This study tests whether personalized nutrition and exercise plans can reduce frailty and improve body composition in prostate cancer survivors who are on hormone therapy (ADT). Fifty participants will receive diet advice, exercise coaching, and educational sessions. Researchers …

This study follows 1000 men with an enlarged prostate who are receiving Rezum water vapor therapy, a minimally invasive steam treatment. The goal is to see how well it relieves urinary symptoms and improves quality of life over 5 years. Researchers will track symptom scores, urin…

This study tests whether two home-based exercise programs—walking or high-intensity cycling—can improve fitness and reduce fatigue in men with metastatic prostate cancer who are starting hormone therapy. Twenty-four participants will exercise at home for 12 weeks, with remote mon…

This study tests the safety of a temporary implant called iTind, placed for 5-7 days, against the permanent UroLift system for men with enlarged prostate symptoms. About 206 men aged 50 and older will be randomly assigned to one treatment. The main goal is to see which causes few…

This study tests whether exercising with others, including some social time, can reduce feelings of loneliness in older men (65+) who have had prostate cancer. 150 participants will be assigned to one of three groups: socially enhanced group exercise, regular group exercise, or e…

This study compares two common surgeries for men with an enlarged prostate causing urinary problems: standard TURP and a newer technique called bipolar enucleation (BEEP). About 120 men with moderate-sized prostates will be randomly assigned to one surgery. Researchers will measu…

This study compares two common surgeries for an enlarged prostate (BPH): a newer laser technique (MoLEP) and a standard electrical procedure (Bi-TURP). About 130 men with moderate to severe symptoms will be randomly assigned to one surgery. The main goal is to see which approach …

This study is testing whether a 21-day spa program—including mineral water baths, exercise, and diet—can improve kidney function and reduce symptoms in 150 adults aged 40-70 with chronic kidney or urinary tract diseases. Participants receive standard spa care at a resort in the C…

This pilot study is testing whether intermittent fasting (with an optional plant-rich diet) is practical and helpful for 30 men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy). The main goal is to see if patients can stick with the diet, not …

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study tracks 500 men aged 30-75 who have specific genetic changes linked to prostate cancer but have not been diagnosed. Researchers will monitor their health over time using yearly exams, blood tests, and MRI scans to understand how these genes affect cancer risk. The goal …

This study collects blood, urine, saliva, and tissue samples from nearly 6,000 people who have or may have cancer, including rare inherited forms. The samples are stored and used for research to understand the genetic and molecular basis of cancer. No new treatment is being teste…

This study is testing a web-based tool called CARE that gives cancer patients information about treatment costs, health insurance, and financial resources. About 430 adults with gynecologic, prostate, lung, or colorectal cancer will use the tool to see if it helps them feel more …

This study looks at whether a special MRI scan (mpMRI) can better monitor prostate cancer in men who choose active surveillance instead of immediate treatment. About 500 men with low-risk prostate cancer will get regular MRIs, biopsies, and blood tests over several years. The goa…

This study explores whether a 7-day water-only fast or ketone supplements are safe and doable for men with prostate cancer. The idea is that fasting may change the body's metabolism and boost immune cells to better attack cancer. Researchers will track side effects and how many p…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study looks at heart-related side effects in older men with advanced prostate cancer treated with enzalutamide or darolutamide. Researchers will analyze existing health records from 3,000 men aged 55 and older to compare rates of heart attacks, strokes, and heart-related dea…

This study tests whether a short video can help more minority patients with prostate cancer join clinical trials. Researchers at LBJ Hospital will show the video to 60 patients and ask them questions before and after. The goal is to find a simple way to make cancer research more …

This study tests an artificial intelligence (AI) tool designed to help doctors and physicists review radiation treatment plans for cancer patients before therapy begins. The AI highlights differences in how providers plan treatments and flags potential warning signs, aiming to re…

This study aims to help African American cancer survivors learn about and get genetic testing for hereditary cancer risks. Researchers are adapting an online educational program to be culturally relevant, with input from community leaders and genetics experts. About 85 participan…

This study tests a digital app called the Genetics Adviser for Mainstream Care (GA-Mainstream) that educates cancer patients about genetic testing and delivers their results. Researchers want to see if using the app reduces distress and improves the patient experience compared to…

This study follows 2,000 men with prostate cancer who have certain gene mutations. Researchers will track their health over many years to see how these genes relate to cancer growth, treatment response, and survival. Participants do not need to visit the hospital regularly; most …

This observational study will follow 100 Japanese men with low-volume metastatic hormone-sensitive prostate cancer who are receiving darolutamide plus standard hormone therapy and chemotherapy. Researchers will collect medical records to see how many men achieve very low PSA leve…

This study is gathering medical records and imaging data from 10,000 men with prostate cancer or at high risk. Researchers aim to find patterns in scans that could help diagnose and treat the disease more effectively. No new drugs or procedures are being tested.

This study is testing a new PET-CT scanner that takes high-resolution images of tissue removed during cancer surgery. Researchers want to see if these images match lab results and help surgeons make better decisions. The study will include 850 people with prostate, breast, head a…

This study compares two imaging methods—micro-ultrasound and MRI—for monitoring prostate cancer in men on active surveillance. Researchers will perform biopsies guided by each technique to see which better detects cancer progression. The goal is to determine if micro-ultrasound c…

This study monitors the safety and effectiveness of darolutamide (Nubeqa) in 600 Korean men with non-metastatic or metastatic hormone-sensitive prostate cancer. Participants receive the drug as part of their normal care and are followed for one year. Researchers track side effect…

This study uses detailed MRI scans and targeted biopsies to investigate why some prostate cancers come back after radiation therapy. Researchers will follow 300 men who are scheduled for radiation or whose cancer has returned after earlier treatment. The goal is to better underst…

This study collects blood, urine, saliva, and tumor tissue from 3,000 men with prostate cancer to investigate genetic changes that cause the disease. Participants may also undergo imaging and answer quality-of-life questions. The goal is to better understand prostate cancer and l…

This study analyzes anonymous prescription records from Australian databases to see how men with advanced prostate cancer are actually treated. Researchers will look at which drugs are used, patient ages, and how well people stick to their medication. The goal is to learn from re…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study compares spinal anesthesia to general anesthesia in men undergoing open simple prostatectomy for an enlarged prostate. The goal is to see if spinal anesthesia leads to less postoperative bleeding, such as fewer blood transfusions or less need for bladder irrigation. Ei…

This study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…

This study looks at why some prostate cancers become resistant to a targeted radiation treatment called 177Lu-PSMA. Researchers will take small tissue samples (biopsies) from tumors in 30 patients before and after therapy. The goal is to find genetic changes that cause resistance…

This study observes 400 men in Russia with aggressive, high-volume metastatic hormone-sensitive prostate cancer. Researchers will track which treatments doctors use (like hormone therapy, chemotherapy, or radiation) and test blood samples for genetic mutations. The goal is to und…

This study aims to find out if chronic pelvic pain conditions like prostatitis and interstitial cystitis can be inherited. Researchers will collect DNA and urine from 500 participants, including family members, to look for genetic links. The goal is to better understand the cause…

This study looks at whether special breathing exercises can help the brains of people with multiple sclerosis or cancer, as well as their caregivers. Researchers will use MRI scans to see how breathing affects oxygen flow in the brain. The goal is to understand the connection bet…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This registry gathers real-world information from thousands of men treated with high-intensity focused ultrasound (HIFU) for prostate cancer using the Focal One device. The goal is to monitor safety and track cancer control through routine PSA tests and MRI scans. By collecting d…

This study tests whether a questionnaire can help doctors spot side effects early in people who have finished treatment for breast or prostate cancer. About 200 survivors will either use the questionnaire or receive standard care. The goal is to see if active monitoring improves …

This study is looking for better ways to detect prostate cancer early in men who have a high genetic risk. Researchers will test urine samples and PSA levels in 200 men aged 35-70 with certain gene mutations. The goal is to see if these tests can predict aggressive prostate cance…

This study compares a new formulation (AJU-G721) of a drug used for benign prostatic hyperplasia (BPH) to the original version (G721R) in healthy adult men. The goal is to see if the two versions are absorbed and processed by the body in the same way. Participants receive a singl…

This study looks at how the pressure settings on a breathing machine during robot-assisted prostate surgery affect the lungs afterward. Researchers will use lung ultrasound to check for changes in lung health. The goal is to find better ways to set the breathing machine to protec…

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that might explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. No treat…

This study is looking at how common low vitamin D levels are among Black men with prostate cancer, and whether vitamin D supplements can improve their immune function. Researchers will measure vitamin D and immune markers in blood samples before and after supplementation. The goa…

This study looks at how much fluid patients should receive during robotic prostate surgery. It compares a standard approach with a more restricted one, using a non-invasive heart monitor to guide decisions. The goal is to see which method keeps tissues better perfused, measured b…

This study looks at whether men with prostate cancer who have hot flashes from hormone therapy will consistently wear a smartwatch to track their symptoms. For 4 weeks, 18 participants will wear the watch, log hot flashes by pressing a button, and complete daily surveys. The goal…

This study is for people with advanced prostate cancer that has spread to bones or lymph nodes and is no longer responding to standard treatments. Researchers want to find the largest total volume of cancer spots that can be safely treated with a precise type of radiation called …

This study is collecting prostate cancer tissue from 16 men with metastatic prostate cancer to analyze the tumor microenvironment—the cells and structures around the tumor. Researchers will use advanced genetic and molecular tests to understand how the immune system interacts wit…

This study is figuring out what normal PSA levels are for trans women and non-binary people who have a prostate. Researchers will measure PSA in 500 volunteers aged 40 and older who are on hormones or have had lower surgery. The goal is to help doctors better detect prostate canc…

This study tracks 270 men with metastatic hormone-sensitive prostate cancer to see how faithfully they take their apalutamide pills over the first year. Researchers will use questionnaires to measure adherence and identify who is at risk of skipping doses. The goal is to learn wh…

This study is creating a large database of medical information and blood samples from 350 adults receiving metabolic radiotherapy for thyroid, prostate, or neuroendocrine cancers. The goal is to provide researchers with valuable data to better understand these treatments. No new …

This study provides long-term follow-up for people who previously received gene therapy or other immunotherapy for cancers like prostate, liver, breast, colon, or lung cancer. Participants will have annual health check-ups or phone calls for up to 15 years to monitor for any long…

This study compares two levels of patient navigation—high-intensity versus low-intensity—to see which helps more people with prostate or kidney cancer enroll in clinical trials. About 90 participants will be randomly assigned to receive either extra support from a patient navigat…

This study is testing whether a new genetic test (called PCAI ImmunoScore) can predict how well men with high-risk prostate cancer will respond to the drug darolutamide before surgery. About 100 participants will take darolutamide for 3-4 months, then have their prostate removed.…

This study follows 300 men with metastatic castration-resistant prostate cancer who are taking olaparib in everyday medical practice. Researchers will track how long patients stay on the drug, how well it controls the cancer, and any side effects. The goal is to learn how olapari…

This study follows 278 men with advanced prostate cancer who are already receiving Pluvicto as part of their routine care in South Korea. Researchers will monitor side effects and how well the drug controls the cancer over time. No new treatment is given—this is purely an observa…

This study is a registry that collects information from 1,000 men with prostate cancer who receive focal therapy using high-intensity focused ultrasound (HIFU) or irreversible electroporation (IRE). No new treatment is given—researchers simply record patient details, disease feat…

This study follows 500 men with metastatic castration-resistant prostate cancer who are receiving lutetium-177 vipivotide tetraxetan (a radioactive drug) as part of their routine care. Researchers will measure quality of life, pain, and disease progression over time using patient…

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study looks at how well a telehealth program called National TeleOncology works for veterans newly diagnosed with lung, colorectal, prostate, or breast cancer. Researchers will track how many veterans use telehealth visits and whether the program affects the quality of care …

This study is for men with intermediate- or high-risk prostate cancer who will receive hormone therapy and radiation. Researchers want to see if using a special PET scan (PSMA PET) during hormone therapy can help doctors better target remaining cancer with radiation while avoidin…

This study follows 106 men who have had surgery for prostate cancer to see how well they recover bladder control, sexual function, and overall health. Participants will receive standard care plus optional exercise programs. The goal is to better understand recovery timelines and …

This study brings together a panel of prostate cancer specialists to agree on the most important pieces of information that should be included in medical records. The goal is to create a standard way to report key data, making it easier for doctors to manage patients from diagnos…

This study compares three different blood tests (CellSearch, Parsortix, and SmartCatch) to see which one best detects circulating tumor cells in patients with metastatic breast or prostate cancer. Researchers will take blood samples from 54 patients before they start a new treatm…

This study follows 80 men aged 65 and older with prostate cancer in Ireland. Researchers will measure frailty, daily functioning, and quality of life over 12 months. The goal is to see how well current frailty screening tools predict health outcomes, helping doctors tailor care f…

This pilot study is testing whether taking endocrine therapy in the morning or evening makes a difference for people with metastatic breast or prostate cancer. Fifty participants will be randomly assigned to take their medication either within an hour of waking or within an hour …

This study follows men with low-risk prostate cancer who have chosen active surveillance—monitoring the cancer over time rather than treating it right away. Researchers will collect data for years to learn which signs predict that the cancer may become aggressive. The goal is to …

This study is a large international registry that will follow at least 5,000 men with advanced prostate cancer for five years or more. Researchers will collect detailed information on treatments, side effects, and quality of life to see which approaches work best. The goal is to …

This study looks at men with urinary retention who need a catheter before having prostate laser surgery (HoLEP, ThuLEP, or ThuFLEP). Researchers want to see if the length of time with a catheter affects how well the surgery works. They will measure changes in urinary symptoms, fl…

This study is testing whether an 8-minute educational video can effectively prepare cancer patients for genetic testing, compared to standard genetic counseling. Over 1,000 adults with various cancers will participate. The goal is to see if the video is acceptable and improves un…

This study follows 837 men with high-risk prostate cancer who choose either robot-assisted surgery or radiation therapy (with or without hormone therapy). Researchers will compare quality of life, side effects, and cancer control over time. The goal is to help patients and doctor…

This study is developing an AI system that tracks tumors and organs during radiation therapy without needing physical markers. Researchers will use existing patient data to train and test the AI. If it works, it could help doctors target radiation more accurately. The study invol…

This study tests a new tool called TRTRM that predicts which older cancer patients are at high risk for severe side effects from treatment. Researchers will use the tool to adjust drug doses and monitoring for patients aged 65 and older with solid tumors. The goal is to see if th…

This study is testing a special MRI scan that uses a substance called hyperpolarized pyruvate to see how well it can monitor prostate cancer in patients who are not receiving treatment. About 60 men with low- to intermediate-risk prostate cancer will be scanned to measure how the…

This study tests whether a network of peer genetic coaches can help African American men with metastatic prostate cancer overcome barriers to genetic testing. The coaches are trained to provide education, address concerns, and guide men through the testing process. The goal is to…

This study follows 300 men with a type of advanced prostate cancer that no longer responds to hormone therapy. Participants receive a targeted radiation treatment called lutetium-177 vipivotide tetraxetan as part of their normal care. Researchers will track how long the cancer st…

This study looks for better ways to find aggressive prostate cancer early in people who have a genetic risk. Researchers will collect blood, urine, and tissue samples from 450 participants to learn more about the genetics of this disease. The goal is to improve future screening a…

This study looks at whether artificial intelligence (AI) can help radiologists find prostate cancer on MRI scans. About 150 men aged 55-80 who are scheduled for a prostate biopsy will take part. The AI software will be compared to radiologists reading the scans alone. The goal is…

This study looks at how well a short course of hormone therapy (ADT) works in men with high-risk prostate cancer that hasn't spread. Researchers use a special PET/CT scan to measure changes in cancer activity before and after treatment. About 50 men will take part, and they will …

This study aims to validate a gene test that identifies oxygen-starved (hypoxic) tumours in bladder and prostate cancer patients. About 30 participants will provide tumour samples and blood, and some will have MRI scans. The goal is to see if this test can help doctors choose mor…

This study is for people with advanced cancers who are taking long-term targeted treatments. Researchers want to learn about their experiences through interviews. The goal is to find better ways to support these patients. The study is currently recruiting 75 participants.

This study is testing whether a website with a virtual community health educator can help Black and Hispanic cancer patients in Florida learn about and sign up for clinical trials. About 350 adults will be randomly assigned to either a standard information portal or one with a vi…

This study follows 320 men with prostate cancer who receive a hydrogel spacer (SpaceOAR) before radiotherapy. The spacer is placed between the prostate and rectum to protect healthy tissue. Researchers will collect data from medical records and patient questionnaires over three y…

This study looks at whether exposure to chlordecone, a pesticide banned in 1993 but still present in the environment, is linked to prostate cancer in men from Martinique. Researchers will compare 3600 men with and without prostate cancer, measuring chlordecone levels in blood and…

This study is testing a software tool that uses DNA from a blood sample to predict the risk of blood clots returning in people with cancer who have finished 3-12 months of blood thinner treatment. The goal is to see if a low-risk result means it's safe to stop blood thinners with…

This study is for people already in the SYNERGY-201 trial, which tests a drug combination for prostate cancer. Researchers want to see if a marker called CXCR2 can predict who will respond well to the treatment. Blood samples and optional tumor biopsies will be collected over tim…

This study follows 102 men with metastatic hormone-sensitive prostate cancer who are taking standard drugs (abiraterone, apalutamide, enzalutamide, or darolutamide) plus hormone therapy. Researchers will check thinking skills, fatigue, mood, and sleep at the start, 3 months, and …

This study looks at whether a specific gut bacterium, Akkermansia muciniphila, can predict how well men with advanced prostate cancer respond to a common hormone therapy (abiraterone acetate). Researchers will collect stool and blood samples from 52 men over three months to track…

This study interviews 24 men with prostate cancer to learn how they feel about breast-related side effects, such as gynecomastia (enlarged breasts), from treatment. The goal is to understand what matters most to patients when choosing therapies. Results will help design a future …

This study is testing whether a special type of scan called PSMA PET can better monitor how prostate cancer responds to treatment. Researchers will scan 110 men with high-risk prostate cancer before and after treatment to see if changes in the scan match standard measures like PS…

This study is testing whether an artificial intelligence (AI) system can automatically measure the amount of cancer seen on PSMA PET-CT scans in 1,500 men with prostate cancer. The AI will calculate tumor volume and uptake, and researchers will see if these measurements can predi…

This study is creating a worldwide registry to track how well different surgical treatments work for benign prostatic hyperplasia (BPH), a condition where the prostate gland enlarges and causes urinary problems. Researchers will collect data from 7,500 participants to compare sym…

This study compares three surgical methods for removing the prostate in men with prostate cancer: robot-assisted laparoscopy, standard laparoscopy, and open surgery. Researchers will track urinary and erectile function before and after surgery in 2,000 participants. The goal is t…

This study looks at how people with BRCA1/2 gene mutations react to additional genetic risk testing for prostate cancer. Researchers want to understand how this information affects their decisions about cancer screening. The study involves 150 men aged 45-70 who carry a BRCA1/2 m…

This study uses online surveys to learn about the real-life experiences of people diagnosed with cancer and their caregivers. Researchers want to understand the emotional, physical, social, and financial challenges they face. The goal is to use this information to improve support…

This study aims to improve treatment for aggressive prostate cancer by growing 3D mini-tumors from patient samples in the lab. Researchers will compare two techniques to see which better predicts how a patient's cancer will respond to radiation or drugs. The goal is to help docto…